FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims

PS2002_FDA EMAILS_400255669_1200.jpg
Drug pricing was backdrop for FDA approval of Ruzurgi.

More from US FDA

More from Agency Leadership